The slide shows the seven key steps that make up a systematic approach to benefit-risk assessment for medicines. Source: The CIRS Benefit-Risk Research.

Slides:



Advertisements
Similar presentations
Information technology for surveillance Can information tools improve surveillance? Denis Coulombier ECDC.
Advertisements

Slide 1www.caa.co.uk UK State Safety Programme (SSP) UK experience & Issues Ben Alcott UK CAA 29 March 2010.
CIRAS PROJECT OVERVIEW
© IPA 2011 Governance Challenges in Healthcare Aidan Horan Institute of Public Administration 2 nd June 2011.
Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons,
Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward Francois Dionne- Centre for Clinical Epidemiology.
© Grant Thornton UK LLP. All rights reserved. Review of Partnership Working Vale of Glamorgan Council Final Report- July 2008.
Seite Slide 1 LED Maturity Assessments of Eastern Cape Municipalities: Cacadu, Amathole, Chris Hani Presentation to SALGA EC Economic.
Systematic planning as an approach to technology implementation: provides a rationale for the technology and related resources.
 ACORD London IT Club 26 February 2004 Susan Savage.
UK Link Programme Update to PNUNC June 17 th 2013.
DANIDA’s Experience of Results Managing for Development Results Peter Ellehøj – Quality Assurance Department November 2011.
Performance Assurance 21 st May Value Chain. Value Chain Xoserve would like to propose an approach to further aid the development of the Performance Assurance.
Project management Topic 4 Business Case.
Presented by. Information! Information is a key resource for all enterprises. Information is created, used, retained, disclosed and destroyed. Technology.
COBIT 5 Executive Summary © 2012 ISACA. All rights reserved.1.
Agency Briefing - Overview
Planning for Curriculum Framework Implementation.
1 Improving the agenda for SWITCH for nonprescription Medicines Sheila Kelly WSMI September 2015.
ROLE OF INTERNAL AUDIT IN STRATEGY MONITORING AND EVALUATION
COBIT 5 Executive Summary
School – Based Assessment – Framework
An Overview on Risk Management
Prof. Dr. Dan Dumitru Popescu
MAXIMISING VALUE FOR MONEY SUBJECT TO COST CONTAINMENT
Regulatory agency and pharmaceutical company responses mapped to the 10 Quality Decision Making Practices (n=76) Legend Best practice Needs improvement.
Cesar Cordova-Novion Deputy Head of Programme Regulatory Reform, OECD
Project Management and Monitoring & Evaluation
Financial Literacy Strategies - Sharing Singapore’s Experience
UK Link Programme Update to PNUNC August 13th, 2013
Presentation to the Canberra Evaluation Forum
Strategic Planning.
ARNBC Issues Workshop CV Network of ARNBC September 15, 2016 ARNBC AGM
APS Strategic Plan Steering Committee
9/16/2018 The ACT Government’s commitment to Performance and Accountability – the role of Evaluation Presentation to the Canberra Evaluation Forum Thursday,
COBIT 5 Executive Summary
Project Management Tools
Organization Audit, Risk and Compliance (ARC)
ICT-enabled assistive systems based on non-invasive BCI
Goals and documentation of quality decision-making practices
COBIT 5 Executive Summary
What do we need to learn about the Key Element?
Figure 4 Precision prescribing
Scientific competence Communication and transparency
Sally Kendall Department of the Environment, Transport and the Regions
Regulatory Responses (n=11) Company Responses (n=20)
Building quality in HTA process and decision making
Rollout time breakdown: 24 common NASs in 7 jurisdictions
Regulatory Responses (n=11) Company Responses (n=20)
WHAT is evaluation and WHY is it important?
COBIT 5 Executive Summary
DIAGNOSTIC FRAMEWORK: National Accounts and Supporting Statistics
Directorate-General Energy and Transport
THE INSPECTION SYSTEM AND THE SCHOOL EXTERNAL EVALUATION
Debriefing of the Workshop on Sector Approaches Sarajevo – March 2010
Patient Involvement in the Development and Use of Safe Medicines Introductory Section – Concepts to Consider CIOMS XI WG Second Meeting October 23-24,
ICT-enabled assistive systems based on non-invasive BCI
Doing Assessments Jointly
WORKSHOP ONE DISCUSSION TOPICS
Effective Risk Management in Decision Making Process
Investing in Data Management Capabilities
Assessment of quality decision making in regulatory agencies and pharmaceutical companies with QoDoS (Quality of Decision Making Orientation Scheme) Not.
WORKSHOP “Emerging environmental pollutants: key issues and challenges” Stresa, Italy June 2006.
DIAGNOSTIC FRAMEWORK: National Accounts and Supporting Statistics
Are agencies interested in adaptive licensing?
The UMBRA Eight-Step Benefit-Risk Framework
Project Manager, EA, the REC
UNECE International Conference
And now the Framework WP4.
Establishing HTA Impact Evaluation From Day One Ruth Louise Poole
Presentation transcript:

The slide shows the seven key steps that make up a systematic approach to benefit-risk assessment for medicines. Source: The CIRS Benefit-Risk Research Programme, which has the objective of achieving an internationally accepted approach for the systematic, routine and standardised documentation of decision making in the benefit-risk assessment of medicines. The next annual Workshop on the topic of Benefit-Risk is Visualising benefit-risk: The key to developing a framework that informs stakeholder perspective and clarity of decision making, which will take place 16-17 June 2011 in Washington, DC. Recent CIRS publications on the topic of benefit-risk include: Mussen F, Salek S and Walker SR, eds. Benefit-Risk Appraisal of Medicines: A Systematic Approach to Decision Making. John Wiley: Surrey, UK. 2009. http://www.wiley.com/WileyCDA/WileyTitle/productCd-0470060859.html Walker S, McAuslane N, Liberti L, Salek S. Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment. Clin Pharmacol Ther. 2009;85:241-246. Liberti L, McAuslane N, Walker S. Progress on the development of a benefit/risk framework for the evaluation of medicines. Regulatory Focus. March 2010.